Related references
Note: Only part of the references are listed.Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy
Allison Barz Leahy et al.
BLOOD (2022)
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Adam J. Lamble et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621
Maureen M. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
Naveen K. Mehta et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
Joseph P. Loftus et al.
HAEMATOLOGICA (2021)
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy
Semjon Willier et al.
BLOOD (2021)
KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy
Adam J. Lamble et al.
BLOOD (2021)
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
Janine Stutterheim et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Shaun Cordoba et al.
NATURE MEDICINE (2021)
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A. Brown et al.
LEUKEMIA (2021)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel et al.
NATURE MEDICINE (2021)
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Kathryn M. Cappell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
Haiying Qin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors
Ahmad S. Alotaibi et al.
BLOOD CANCER DISCOVERY (2021)
An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity
Yik Andy Yeung et al.
MOLECULAR THERAPY (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tuning the Antigen Density Requirement for CAR T-cell Activity
Robbie G. Majzner et al.
CANCER DISCOVERY (2020)
Characterization of a Novel FLT3 BITE Molecule for the Treatment of Acute Myeloid Leukemia
Bettina Brauchle et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
Cesar Sommer et al.
MOLECULAR THERAPY (2020)
Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia
Christine Karbowski et al.
TOXICOLOGICAL SCIENCES (2020)
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah et al.
NATURE MEDICINE (2020)
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Sneha Ramakrishna et al.
CLINICAL CANCER RESEARCH (2019)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Multi-Specific CAR Targeting to Prevent Antigen Escape
Zachary Walsh et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies
Nese Cakmak-Goeruer et al.
LEUKEMIA (2019)
Opportunities for immunotherapy in childhood acute myeloid leukemia
Adam J. Lamble et al.
Hematology-American Society of Hematology Education Program (2019)
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Hamid Bolouri et al.
NATURE MEDICINE (2018)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Ying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Haiying Qin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
L. Chen et al.
LEUKEMIA (2017)
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
E. Mejstrikova et al.
BLOOD CANCER JOURNAL (2017)
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Katherine Tarlock et al.
CLINICAL CANCER RESEARCH (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Sarah K. Tasian et al.
BLOOD (2017)
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
FLT3 Activation Improves Post-Myocardial Infarction Remodeling Involving a Cytoprotective Effect on Cardiomyocytes
Otmar Pfister et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia
M. Hofmann et al.
LEUKEMIA (2012)
Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia
Ronald W. Stam et al.
BLOOD (2007)
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples
O Piloto et al.
CANCER RESEARCH (2006)
MLL-rearranged leukemias:: Insights from gene expression profiling
SA Armstrong et al.
SEMINARS IN HEMATOLOGY (2003)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Share Paper
